Biosimilar to Infliximab Switch Yields Similar IBD Outcomes (CME/CE)

(MedPage Today) — No significant changes in clinical remission, and no new safety signals

Source link

Related posts

Clinical value of DPOC for detecting and removing residual common bile duct stones (video)


Modern-day environmental factors in the pathogenesis of osteoarthritis


No Surgical Gains from Accelerated Infliximab in Acute UC


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy